Lisa Ricciardi

Ms. Ricciardi joined Cognition Therapeutics in March 2019 as a member of the Board of Directors and was appointed CEO in March 2020. She possesses a unique perspective and breadth of knowledge formed during a career working in multiple industry segments, including drug development and commercialization, healthcare services, and genomics. She has a proven track record launching large-market therapeutics as well as negotiating financial and business development agreements, from small to multi-billion-dollar deals.

Before her appointment as interim CEO, Ms. Ricciardi served as an advisor at M.M. Dillon, a boutique life-sciences investment bank, where she provided counsel to biotech companies on transactions with pharma and biopharma companies. Earlier, she was CEO of Suono Bio, a biotech company founded on technology licensed from MIT, which she led through a Series A fundraising. Ms. Ricciardi held senior business development positions at Foundation Medicine, where she negotiated the $1.03 billion transformational agreement with Roche in 2015, and at Medco, where she was involved in numerous deals including the $29 billion acquisition of Medco by Express Scripts in 2011.

In addition to her role at Cognition Therapeutics, Ms. Ricciardi is a member of the Board of Directors of United Drug Healthcare Group, a Dublin-based pharmaceutical outsourced supplier. In this role, she serves on the Compensation, Risk/Investment, and Audit Committees. Previous director roles include Sepracor (acquired by Dainippon), Chimerix, and Contrafect. Ms. Ricciardi earned a Bachelor of Arts cum laude in English and religion from Wesleyan University and a Master of Business Administration from the University of Chicago Booth School of Management.